Micreos Pockets €12m For Staphefeckt Products
This article was originally published in Scrip
Executive Summary
Antibacterial-focused Micreos has pocketed €12m for the global development of its antibacterial lysin technology, Endolysin Staphefeckt, as a prescription product to suppress Staphylococcus aureus on the skin of individuals with eczema, rosacea and acne.
You may also be interested in...
Finance Watch: Arteaus Comes Full Circle As Investors Monetize Emgality Royalties
Arteaus sells royalty stream from Lilly's Emgality giving investors a $260m payday. Also, Pfizer spin-out SpringWorks nabs another $125m, Arch Oncology and Prevail Therapeutics close $50m Series B rounds, and Karuna's recent financing grows to $80m.
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.